BridgeBio Oncology Therapeutics Inc. (BBOT) vs Century Therapeutics, Inc. (IPSC)
A side-by-side comparison of BridgeBio Oncology Therapeutics Inc. and Century Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBOT
BridgeBio Oncology Therapeutics Inc.
$3.54HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
IPSC
Century Therapeutics, Inc.
$1.38HealthcareDelayed quote: Oct 6, 2026, 2:15 PM EDT
Total return — BBOT vs IPSC
growth of $100 · dividends reinvested · last 3yBBOT -64.7% (-29.3%/yr)IPSC -66.7% (-30.7%/yr)BBOT compounded faster over this window
BBOT IPSC
BBOT vs IPSC: by the numbers
- •BBOT is the larger company ($283M vs $250M market cap).
- •Both run net losses; BBOT's is the smaller (0.00% vs -8.78% net margin).
Metrics side by side
Valuation
| Metric | BBOT | IPSC |
|---|---|---|
| P/B ratio | 0.88 | 1.08 |
Profitability
| Metric | BBOT | IPSC |
|---|---|---|
| Gross margin | 0.00% | 88.00% |
| Operating margin | 0.00% | -13.78% |
| Net margin | 0.00% | -8.78% |
| ROE | -56.36% | -47.25% |
| ROIC | -61.10% | -43.69% |
Growth (annualized)
| Metric | BBOT | IPSC |
|---|---|---|
| Total return CAGR (5Y) | N/A | -42.05% |
Go deeper
Dig into the metrics
BridgeBio Oncology Therapeutics ROECentury Therapeutics ROEBridgeBio Oncology Therapeutics operating marginCentury Therapeutics operating marginBridgeBio Oncology Therapeutics revenue growthCentury Therapeutics revenue growthBridgeBio Oncology Therapeutics free cash flowCentury Therapeutics free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.